Combination of dextromethorphan and memantine in treating bipolar spectrum disorder: a 12-week double-blind randomized clinical trial

International Journal of Bipolar Disorders

Table 3 Difference in outcomes of add-on medication (DM30, MM5, and DM30 + MM5) versus Placebo in BD-II patients

B standardized coefficient, HDRS 17-item Hamilton Depression Rating Scale, YMRS Young Mania Rating Scale, TNF-α tumor necrosis factor α, CRP C-reactive protein, BDNF brain-derived neurotrophic factor, TC total cholesterol, HDL-C high-density lipoprotein-cholesterol, LDL-C low-density lipoprotein-cholesterol, DM30 dextromethorphan (30 mg/day), MM5 memantine (5 mg/day), DM30 + MM5 dextromethorphan (30 mg/day) combined with memantine (5 mg/day), FBS fasting blood sugar
*P < 0.05
^aUsing the Placebo group as a reference group, controlling for age, gender, and treatment duration. The data shown are the interaction term, treatment group, and treatment duration
^bUsing the Placebo group as a reference group, controlling for age, gender, treatment duration, HDRS, and YMRS. The data shown are the interaction term, treatment group, and treatment duration